PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

NCT07739537 · Not yet recruiting

Last updated 2026-08-27

This study tests how people with Type 2 diabetes respond to different treatments based on their genetic makeup.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) study

Participants 100 people Planned (estimated).

Who can join Ages 18–79 · all sexes

Timeline Started 2026-10 · est. completion 2030-09

What this study is testing ClinicalTrials.gov NCT07739537 ↗

Description as written by the study sponsor.

We are conducting a research study to learn how the body responds to food through different genetic pathways and how these responses may change during a short course of orforglipron. Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was approved by the U.S. Food and Drug Administration (FDA) on April 1, 2026, for long-term weight management. In longer studies, it has helped people lose weight and improve blood sugar, blood pressure, and cholesterol. By taking part, you will receive detailed metabolic testing and may receive study results that provide additional information about your blood sugar and metabolic health.

Treatments tested

Orforglipron Drug

Orforglipron challenge after baseline MMTT

Main thing measured	Physiologic characterization by MMTT
Sponsor	Massachusetts General Hospital
Conditions studied	Diabete Type 2, Pharmacogenomic Drug Interaction
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07739537 ↗